T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$2.31B |
| 2 |
Apple
AAPL
|
+$1.58B |
| 3 |
Sherwin-Williams
SHW
|
+$1.37B |
| 4 |
HubSpot
HUBS
|
+$1.32B |
| 5 |
Kenvue
KVUE
|
+$1.25B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.37B |
| 2 |
Lam Research
LRCX
|
+$1.54B |
| 3 |
Applied Materials
AMAT
|
+$1.33B |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$1.19B |
| 5 |
Halliburton
HAL
|
+$1.16B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.32% |
| 2 | Healthcare | 15.15% |
| 3 | Financials | 10.54% |
| 4 | Consumer Discretionary | 10.48% |
| 5 | Communication Services | 8.71% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2826
ADC Therapeutics
ADCT
$156M
| $91K | ﹤0.01% |
28,831
+6,355
| +28% | +$20K |
|
2827
Sutro Biopharma
STRO
$353M
| $91K | ﹤0.01% |
2,626
| – | – |
|
2828
Treace Medical Concepts
TMCI
$309M
| $91K | ﹤0.01% |
15,604
| – | – |
|
|
BGFV
2829
DELISTED
Big 5 Sporting Goods
BGFV
| $90K | ﹤0.01% |
42,900
+18,100
| +73% | +$38.7K |
|
|
PHLT
2830
DELISTED
Performant Healthcare Inc
PHLT
| $90K | ﹤0.01% |
23,968
+3,664
| +18% | +$12.5K |
|
2831
Alto Ingredients
ALTO
$315M
| $89K | ﹤0.01% |
54,700
| – | – |
|
2832
Larimar Therapeutics
LRMR
$454M
| $89K | ﹤0.01% |
13,460
| – | – |
|
2833
Vanda Pharmaceuticals
VNDA
$314M
| $89K | ﹤0.01% |
18,895
+1,865
| +11% | +$10K |
|
|
WOW
2834
DELISTED
WideOpenWest
WOW
| $89K | ﹤0.01% |
16,873
+2,257
| +15% | +$12K |
|
2835
Angi Inc
ANGI
$176M
| $88K | ﹤0.01% |
3,400
| – | – |
|
|
INZY
2836
DELISTED
Inozyme Pharma
INZY
| $87K | ﹤0.01% |
16,603
+233
| +1% | +$1.21K |
|
2837
Ouster
OUST
$3.33B
| $87K | ﹤0.01% |
13,806
| – | – |
|
|
GAN
2838
DELISTED
GAN Ltd
GAN
| $86K | ﹤0.01% |
48,300
| – | – |
|
2839
Quantum-Si Incorporated
QSI
$182M
| $86K | ﹤0.01% |
97,327
+37,600
| +63% | +$36.5K |
|
2840
Revolution Medicines Inc Warrant
RVMDW
$124M
| $85K | ﹤0.01% |
606,180
| – | – |
|
2841
Vuzix
VUZI
$218M
| $85K | ﹤0.01% |
71,900
| – | – |
|
|
CTEV
2842
Claritev Corp
CTEV
$599M
| $85K | ﹤0.01% |
11,049
+3,644
| +49% | +$42.8K |
|
2843
Tenax Therapeutics
TENX
$64.4M
| $84K | ﹤0.01% |
+24,000
| New | +$86.9K |
|
2844
Amplify Energy
AMPY
$182M
| $83K | ﹤0.01% |
12,562
+285
| +2% | +$1.98K |
|
2845
Talkspace
TALK
$869M
| $83K | ﹤0.01% |
39,328
| – | – |
|
2846
Target Hospitality
TH
$1.61B
| $83K | ﹤0.01% |
10,668
+387
| +4% | +$3.62K |
|
2847
Backblaze
BLZE
$1.2B
| $82K | ﹤0.01% |
12,788
| – | – |
|
2848
Lifezone Metals
LZM
$352M
| $82K | ﹤0.01% |
11,687
| – | – |
|
2849
Veru
VERU
$46.7M
| $82K | ﹤0.01% |
10,611
| – | – |
|
2850
Seer Inc
SEER
$118M
| $81K | ﹤0.01% |
40,900
| – | – |
|
Similar funds
T. Rowe Price Associates's Q3 2024 Portfolio in Review
As of Q3 2024, T. Rowe Price Associates held 3,059 positions worth $869B, up 3.9% from $836B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Trading was light in Q3 2024: portfolio turnover was 4.3%. T. Rowe Price Associates opened 82 new positions and exited 51, leaving the 3,059-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 32% of assets, down from 34% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q3 2024 buy was Lineage Inc: 4,699,854 shares worth $368M.
- T. Rowe Price Associates added most to Advanced Micro Devices in Q3 2024, an estimated $2.31B increase.
- T. Rowe Price Associates's biggest Q3 2024 reduction was NVIDIA, cutting an estimated $4.37B.
- T. Rowe Price Associates fully exited Morphic Holding, Inc. Common Stock in Q3 2024, selling an estimated $75.2M.
- T. Rowe Price Associates's ten largest holdings make up 34% of its $869B portfolio in Q3 2024.
- T. Rowe Price Associates opened 82 new positions and closed 51 in Q3 2024.
- T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $869B.
Based on T. Rowe Price Associates's 13F filing for Q3 2024, filed 14 Nov 2024.